Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Name: Kaimen Rigor review — Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.
Item: Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.
Rating: 100
Author: Alpha1

Zhang Y, Li J, Wang M, Li X, Yan B, Liu J, Shi L, Cao Z, Feng Y, Liu W, Xu Z, Ma R, Gao X, Liu W, Xue J, Ren X, Li X, Song X, Yang Y, Wang Y, Xing Z, Quan F, Pan J, Sun Y, Shi F, Chen X, Yan H, Zhao G, Chen B, Wang C, Zhang L

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03651-5

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/23c84f88-3926-4546-88cf-89e3f9a2fc48" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/23c84f88-3926-4546-88cf-89e3f9a2fc48/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e619f5bdc69806f68ee66f2020f9e6ec0ae781522ef6acef783d5d532ba90892

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Paper source

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 30 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is the reflective total nasal symptom score (rTNSS), a patient-reported symptom score, which is a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD showing IL-4Rα blockade) nor does it cite validated evidence linking rTNSS improvement to long-term clinical outcomes. Although the paper mentions pharmacodynamic markers (TARC, IgE, eotaxin-3) and exploratory biomarkers, these are not directly linked to the primary efficacy claim.
“The primary endpoint was mean change from baseline in daily reflective total nasal symptom score (rTNSS) over the first 2 weeks.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect size is a least-squares mean difference of -1.3 in rTNSS (scale 0-12) compared to placebo. The paper does not anchor this to a minimal clinically important difference (MCID) for rTNSS; it only mentions MCID for RQLQ (0.5 points). The magnitude is small relative to the scale and lacks explicit clinical meaningfulness.
“Compared with the placebo, stapokibart led to a significant improvement in the mean change from baseline in daily rTNSS during the 2-week (least-squares mean difference, −1.3; 95% confidence interval, −2.0 to −0.6; P = 0.0008)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized controlled trial. The design is rigorous with proper randomization, blinding, power analysis, and pre-specified endpoints. All eight rigor dimensions pass, with minor copyedit issues and one unresolved reference flagged.

Both reviewers independently scored all eight dimensions as 'pass' with high confidence, and their evidence was consistent. The study type is interventional (phase 3 RCT). The statistics verification recomputed 6 tests consistently, but coverage is limited to tests with test statistics/df or effect estimates with CIs; threshold-only p-values and resampling-based p-values were not machine-verified. The citation check flagged one reference (the Zenodo code DOI) as not found in the registry, which is a data/code link rather than a citation to prior literature.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple prior studies and meta-analyses on omalizumab and anti-IL-4/IL-4Rα biologics, acknowledges their limitations (cost, lack of seasonal add-on trials), and identifies a gap. The rationale for stapokibart and the specific patient population (eosinophil ≥300) is derived from the phase 2 MERAK trial. Limitations of prior work are addressed by designing a trial during natural pollen exposure.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on SAR burden, limitations of current treatments, and prior biologics trials, and logically links this to the study's objectives.

Evidence

“Previous RCT trials as well as meta-analysis studies have shown the significant efficacy of pre- and co-seasonal administration of omalizumab (an anti-IgE monoclonal antibody) in improving nasal and ocular symptoms, and QOL in patients with SAR during the pollen season”

Main, paragraphs 1-3Find in source

“Nevertheless, there has been an absence of clinical trials evaluating the efficacy of incorporating biologics as a seasonal add-on therapy to SoC treatment during the pollen season for patients with moderate-to-severe SAR.”

Main, paragraph 3Find in source

“Notably, it significantly reduced the daily reflective total nasal symptom score (rTNSS) in a subgroup of patients with blood eosinophil counts of at least 300 cells μl −1 , when exposed to pollen.”

Main, paragraph 4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on SAR burden, limitations of current treatments, and evidence for biologics, and logically links this to the study's objectives.

Evidence

“Despite receiving standard-of-care (SoC) treatment, including H1 antihistamines or intranasal corticosteroids, over 60% of patients with SAR are dissatisfied with their treatment owing to poor symptom control”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 4]

“Our findings from a double-blind, randomized, placebo-controlled, phase 2 trial (the MERAK trial; ClinicalTrials.gov identifier: NCT05470647) indicated that stapokibart was well tolerated and safe in the overall moderate-to-severe SAR population.”

Introduction ¶3Find in source

Randomization was stratified by site using a block size of 4, with a randomization list generated by SAS. Blinding was double-blind with visually indistinguishable vials. Power analysis was based on MERAK data (mean difference -1.50, SD 2.43, power 85%, dropout 10%). Inclusion/exclusion criteria are detailed. Missing data handling (LOCF, non-response) is pre-specified in the SAP. The comparator (placebo) and background therapy serve as controls. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a pre-specified sample size calculation, clear inclusion/exclusion criteria, and appropriate handling of missing data.

Evidence

“Participants were randomized in a 1:1 ratio to receive either stapokibart or the matching placebo. Randomization was stratified by study site via an interactive web response system.”

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting